Antibody Ingredients TRIZ Cases

PD-L1 FFPE IHC screening helps target anti-PD-1 therapy and limit adverse effects.

Humanized anti-hK2 antibodies target prostate cancer while limiting marrow exposure.

This case uses KLRB1-binding antibodies to deplete cytokine-producing cells beyond IL-17 or IL-23 targeting.

This case uses early soluble CD26/DPP4 titer variation to predict anti-CD26 treatment response before RECIST assessment.

CDR-focused antibodies neutralize endotrophin and enhance platinum chemotherapy.

This case pairs an anti-Galectin-9 antibody with tislelizumab to enhance T-cell activity and reduce tumor growth.

See how camphorsulfonic acid with cationic excipients reduces viscosity and aggregation in high-concentration protein injections.

This case uses a hydrophilic linker to reduce anti-HER3 ADC aggregation while preserving camptothecin delivery to resistant tumors.

This case uses antibodies targeting Ara h 1, Ara h 2, Ara h 3, and Ara h 6 to reduce IgE binding and allergic activation.

This case combines EpCAM tumor targeting with CD137 engagement in one binding agent to enhance T-cell activation and proliferation.

This case pairs high-affinity Nectin-4 binding with FFPE-compatible IHC for diagnosis, prognosis, and treatment selection.

Anti-CD24 antibodies block CD24–Siglec-10 signaling, helping macrophages engulf tumor cells and improve chemosensitivity.

This case targets PAG at the immune synapse, enhancing T-cell function and tumor infiltration alongside anti-PD-1 therapy.

This case uses antibodies, small molecules, or aptamers to inhibit or enhance AFP–FcRn binding and regulate AFP activity.

Antibody cocktails block Bet v 1 allergens systemically, addressing limited ocular relief and safety concerns of existing treatments.

This case uses dual allergen-binding antibody domains to block mast cell activation and reduce peanut allergy reactions.

H-1PV DR uses full-length right-end ITRs plus targeted genome changes to improve viral fitness, infectivity, and anticancer activity.

This case uses L9 monoclonal antibodies against PfCSP to block infectious sporozoites and address rising antimalarial drug resistance.

This case uses a transferrin receptor-recognizing antibody to target NK-cell tumors and improve survival in animal models.

CDR-grafted humanized antibody targets PD-L1 specifically, preserving affinity and stability while enhancing T-cell activation.

This case examines high-affinity HER2 antibodies that activate FcR pathways and apoptosis to improve tumor burden reduction.

This case uses defined heavy- and light-chain CDRs and humanization to target PTK7, inhibit signaling, and limit immunogenicity.

This case develops CD39-specific antibodies or fragments that inhibit ATP and ADP hydrolysis to modulate immune responses.

This case combines PD-L1/PD-1 blockade with ADCC and CDC in one antibody to restore T-cell activity and kill tumor cells.

This case uses anti-ILT2 antibodies to block ILT2-HLA-G1 suppression and complement PD-1/PD-L1 therapy across immune cells.

This case examines bispecific amivantamab targeting EGFR and c-Met to improve treatment potential in metastatic colorectal cancer.

This case combines anti-FasL and anti-CD25 therapies to sustain immune activity, improve survival, and prevent tumor relapse.

This case shows how Vβ17/CD123 bispecific antibodies focus cytotoxic T-cell activity on cancer cells while limiting nonspecific activation.

Modified Fc regions boost ADCC and ADCP while preserving CTLA-4 blocking to improve Treg depletion and anti-tumor immunity.

This case combines GRP78-specific antibodies, linkers, and cytotoxic payloads to target cancer cells while easing production toxicity.

This case uses tumor-antigen and CD28 binding to boost local tumor killing while limiting systemic cytokine storms and autoimmune effects.

This case bridges T cells and FSHR-positive ovarian cancer cells to address chemoresistance and improve tumor targeting.

This case uses selective CCR8 binding to remove tumor Tregs, strengthen anti-tumor immunity, and limit effector T-cell depletion.

This case uses segmented heavy and light chains with pairing regions to improve TfR targeting, stability, productivity, and purification.

This case uses monoclonal antibodies to modulate LILRB4, block ApoE binding, restore T cell proliferation, and suppress AML migration.

This case uses anti-PLA2G10 antibodies to inhibit enzyme activity, enhance T-cell tumor infiltration, and treat expressing cancers.

This case pairs selective SIRPα epitope binding with macrophage phagocytosis while avoiding SIRPβ and SIRPγ cross-reactivity.

This oncolytic HSV combines CTLA-4 inhibition with local tumor targeting to reduce off-target toxicity and reach uninjected tumors.

This case combines IgG and scFv fragments with peptide linkers to bridge tumor targeting and PD-1 blockade.

This case isolates high-affinity NKp30 antibody molecules to activate immunity for cancer, autoimmune, and infectious disorders.

This case uses a 12–13 kDa VHH domain to retain αVβ3 binding while improving tissue permeability and angiogenesis diagnosis.

This case develops high-affinity anti-Sema3A antibodies that inhibit activity while supporting cross-species preclinical studies.

A single multi-specific protein activates NK and cytotoxic T cells through multiple receptors for potent BCMA-expressing cancer cell lysis.

This case combines heterodimeric Fc-modified BiTEs targeting CD3 and tumor antigens to improve persistence and limit treatment escape.

This case uses engineered HCDR and LCDR sequences to improve MSLN binding, ADCC, apoptosis, and chemotherapy sensitivity.

Multi-specific proteins engage NKG2D, CD16, and tumor antigens to activate NK cells.

This case uses epitope-specific, cross-reactive CD137 antibodies to enhance anti-tumor responses while limiting autoimmune effects.

3D organoids preserve tumor-stromal-immune interactions for timely immunotherapy response assays.

This fusion molecule masks CD3 binding until tumor proteases cleave the linker, focusing immune-cell activation in cancer tissue.

This case uses opioid-specific sdAbs to bind fentanyl and carfentanil before brain receptors, addressing short naloxone protection.